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2Abstract
In healthy individuals, the vascular endothelium regulates an intricate balance of
factors that maintain vascular homeostasis and normal arterial function. Functional
disruption of the endothelium is known to be an early event that underlies the
development of subsequent cardiovascular disease (CVD) including atherosclerosis
and coronary heart disease. In addition, the rising global epidemic of type 2 diabetes is
a significant problem conferring a significantly higher risk of CVD to individuals in whom
endothelial dysfunction is also notable.
This review firstly summarises the role of endothelium in health and explores and
evaluates the impact of diabetes on endothelial function. The characteristic features of
insulin resistance and other metabolic disturbances that may underlie long-term
changes in vascular endothelial function (metabolic memory) are described along with
proposed cellular, molecular and epigenetic mechanisms. Through understanding the
underlying mechanisms, novel targets for future therapies to restore endothelial
homeostasis and “drive” a reparative cellular phenotype are explored.
Keywords
Diabetes; endothelial function; endothelial dysfunction; metabolic memory; microRNA;
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3Introduction
Largely owing to the vast quantities of energy-dense food consumed in the Western
world, coupled with increasingly sedentary lifestyles, diabetes mellitus (DM) is
considered to be a public health problem of epidemic proportions.1, 2 In the UK alone,
2.9 million people are diagnosed with the disease, with an estimated 850,000 more
undiagnosed.3 DM is recognised as an independent risk factor for cardiovascular
disease (CVD),4 even when under glycaemic control. With up to 75% of mortality in
diabetic patients arising from CVD,5 this is an issue of utmost importance. Endothelial
cell (EC) dysfunction is associated with both diabetes and the pathogenesis of CVD.6
Establishing the causative mechanisms linking these factors could provide essential
insights and inform novel therapeutics.
The aim of this review is to explore the relationship between DM and EC
function/dysfunction, focussing predominantly on cellular and molecular mechanisms
as opposed to clinical manifestations.
Physiological role of endothelium
Forming a vast interface between the blood and surrounding tissues, the endothelium
forms a monolayer comprising the innermost lining of blood vessels. Advances over
recent decades have revealed the complexity of this semi-permeable membrane and
its key role in maintaining vascular homeostasis.7 Whilst facilitating the passage of
substances such as nutrients and leukocytes across the vessel wall, the endothelium
4secretes numerous mediators necessary for normal vascular functioning including
those that regulate vascular tone, coagulation, modulate immune responses and
control vascular cell growth.8
Arguably the most significant endothelium-derived mediator is nitric oxide (NO),
which plays multiple roles in preventing atheroma formation.9 Produced by the action of
endothelial nitric oxide synthase (eNOS), NO diffuses into neighbouring vascular
smooth muscle cells (SMC) activating guanylyl cyclase and producing cGMP and
activating kinases responsible for vascular relaxation.8 Vasodilation via NO synthesis is
well documented in vitro and in vivo. 10-12 Additionally, NO inhibits platelet aggregation,
SMC proliferation and nuclear transcription of leukocyte-adhesion molecules including
vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM).
Arterial wall shear stress,13 and coupling of agonists such as acetylcholine and
bradykinin to endothelial bound receptors 8 are potent stimuli for NO synthesis.
Although these stimuli act via different intracellular mechanisms, each increases NO
production via enhanced expression of eNOS. Other important vasodilatory factors are
endothelium-derived hyperpolarizing factor (EDHF) and prostacyclin (PGI2), the latter
also playing a role in platelet inhibition.8
Conversely, the endothelium is able to secrete the potent vasoconstrictor
endothelin (ET-1), which through its pro-inflammatory and mitogenic effects augments
the pathogenesis of CVD.14 Other endothelial derived vasoconstrictors include
prostaglandin H2 (PGH2), thromboxane A2 (TXA2) and reactive oxygen species (ROS).
EC- bound angiotensin converting enzyme (ACE) catalyses production of the
vasoconstrictive angiotensin II, and ACE inhibitors are commonly used to decrease
5blood pressure.15 Under physiological conditions, the endothelium maintains a fine
balance between anti- and pro-thrombotic states. Whilst NO, prostacyclin and
thrombomodulin favour blood fluidity and are dominant under basal conditions,
‘activated’ endothelium drives an opposing pro-thrombotic state. Under these
conditions plasminogen activator inhibitor-1 and thromboxane, together with von
Willebrand Factor (vWF), a key constituent of the coagulation cascade, are
deleterious.8, 16
Through NO production, the endothelium plays a crucial role in preventing
leukocyte adhesion; however when ‘activated’, expression of adhesion molecules aid
the passage of leukocytes across the vascular wall promoting a proinflammatory
environment. Under these conditions EC produce pro-inflammatory cytokines, including
tumour necrosis factor-alpha (TNF-α), which further augment inflammation.17
Finally, the endothelium plays a key role in angiogenesis initiated by tissue
growth factors, particularly vascular endothelial growth factor (VEGF). The VEGF
receptor is coupled to activation of mitogen-activated protein kinase (MAPK) signalling,
promoting angiogenesis by increasing nuclear transcription of relevant genes. This
mechanism is counteracted by the anti-angiogenic factors angiostatin and
thrombospondin which suppress angiogenesis unless required.8
Endothelial dysfunction
Endothelial dysfunction refers to inability of the endothelium to regulate vascular
homeostasis, and essentially describes “tipping” of the physiological balance in favour
of vasoconstrictive, pro-inflammatory and pro-thrombotic effects 5 that promote
6atherosclerosis. As such, abnormalities in endothelial function are detected early in the
development of CVD, often before symptoms are clinically evident.16
Given the vast range of vasoprotective effects of NO, the term endothelial
dysfunction generally refers to reduced NO bioavailability, through decreased eNOS
expression.16 Procedures employed to evaluate endothelial dysfunction measure
blunted vasodilatory responses to certain agonists.5 Indeed, by this method impaired
endothelial-dependent vasodilation in patients with confirmed CVD,18-21 and importantly
in those who carry risk factors for future CVD events,22 have been demonstrated. This
suggests that endothelial dysfunction is the commonality by which these risk factors,
particularly those associated with the metabolic syndrome, lead to CVD development.
This point is underscored by reports that endothelial dysfunction appears to reverse
when lifestyle changes and modulatory drug therapies are implemented.23 DM is one of
the aforementioned risk factors whose association with endothelial dysfunction will now
be evaluated.
Endothelial dysfunction in diabetes mellitus
Current evidence links endothelial dysfunction to T1DM and T2DM, through
demonstration of impaired endothelial-dependent vasodilation.24-26 Despite many
proposed mechanisms for this relationship, the definitive pathogenesis remains unclear,
possibly because diabetes patients usually display multiple homeostatic imbalances
alongside the typically described hyperglycaemia. Such disturbances induce
endothelial dysfunction independently of the presence of diabetes, indicating a
7multifactorial aetiology rather than hyperglycaemia per se.27-29 The following sections
will evaluate these factors.
Selective insulin resistance
In addition to its role in glucose homeostasis, insulin activates intracellular signalling
pathways critical for maintenance of healthy endothelium, the most vasoprotective of
which is the phosphoinositide-3 kinase (PI3-K)/Akt pathway (Figure 1). Through this
pathway, enhanced eNOS expression and activation (phosphorylation) is mediated.30,
31 In contrast, activation of the mitogen-activated protein kinase (MAPK)/ERK pathway,
promotes expression of ET-1 and a less beneficial outcome of cellular proliferation.32
In physiological circumstances, the PI3-K pathway predominates to regulate normal
vasomotor control,33 but it is well accepted that in insulin resistance that characterises
T2DM, there is a selective deficiency of the PI3-K pathway, while signalling via the
MAPK pathway is unaffected.34, 35 Moreover, this selective resistance promotes
hyperinsulinaemia, resulting in further stimulation of MAPK signalling.36 The outcome
therefore is that of pro-atherogenic signalling that is clearly detrimental to the
vasculature.37 This signalling deficiency has been demonstrated experimentally in
obese Zucker rats, in which defective PI3-K/Akt signalling consequently resulted in
decreased NO bioavailability.34
Pro-inflammatory signalling
T2DM is associated with a state of chronic systemic inflammation; elevated levels of
circulating inflammatory markers are observed in patients with diabetes and obesity 38,
839 and are believed to confer a pathological EC phenotype. A diverse range of harmful
stimuli have been shown to contribute to vascular complications in diabetes. These
include proinflammatory cytokines, chemokines, adhesion molecules and transcription
factors (summarised in Table 1) and have been reviewed recently. 40
Animal models of obesity have identified adipose tissue as a site of inflammatory
cytokine production, with accompanying elevated plasma levels of TNF-α.41, 42 TNF-α 
activates nuclear factor kB (NFkB), a transcription factor able to further stimulate
expression of inflammatory genes.43 NFkB is also activated by free fatty acids and the
receptor for advanced glycation end products (RAGE), both of which are characteristic
of the diabetic milieu.16 Evidence suggests that overexpression of either TNF-α or IkB 
kinase mediates the development of insulin resistance. Obese mice with null mutations
in the TNF-α gene display significantly improved insulin sensitivity.44 Indeed, NFkB that
is permanently present in the cell could be viewed as the “first responder” to many
inflammatory signals due to rapid activation of its downstream pathways. More recently,
new pharmacological roles for the salicylate anti-inflammatory drugs have emerged
regarding their ability to decrease insulin resistance via inhibition of IkB kinase.
Preliminary results from the TINSAL-T2D clinical trial advocates their use in glucose-
lowering, presumably as a consequence of improved insulin sensitivity.45 The
association of insulin resistance with inflammation implies that the latter adversely
impairs the NO-producing PI3-K/Akt pathway, ultimately reducing NO bioavailability.
Exposure of cultured EC to TNF-α leads to impaired eNOS expression;46 inferring that
reduced bioavailability of NO nullifies its otherwise significant anti-inflammatory role,
thus augmenting formation of inflammatory atherosclerotic lesions.
9Oxidative stress
Oxidative stress is commonly implicated as an important unifying mechanism in
conferring endothelial injury (see Figure 2). The term refers to the accumulation of
reactive oxygen species (ROS) such as superoxide anion (O2•
-), when production
exceeds the capability of the anti-oxidant system to remove them.47 A key adverse
effect of oxidative stress is diminished NO bioavailability; either through direct
degradation by ROS, or alterations in the functional capacity of eNOS. Direct reaction
of NO with O2•
- yields peroxynitrite (ONOO-), a highly potent oxidant capable of altering
the functions of multiple intracellular molecules, including those related directly to the
NO pathway.48 Additionally, ONOO- serves to uncouple eNOS from its critical co-factor
tetrahydrobiopterin (BH4), resulting in preferential formation of O2•
- in the place of NO
and hence further exacerbation of the problem 49. In the setting of insulin resistance,
experimental evidence has implicated endogenous ONOO- as a down-regulator of the
PI3-K/Akt pathway.50, 51
Aside from uncoupled eNOS, significant sources of O2•
- include xanthine
oxidase, NADPH oxidase and mitochondria.47 Mitochondria produce negligible ROS in
physiological circumstances but greatly increase O2•
- output when high glucose
concentrations increase the proton gradient within the electron transport chain.52
Recent evidence has also implicated mitochondrial dynamics, namely increased
mitochondrial fission and fragmentation, as contributing factors to ROS production in
DM.53
Anti-oxidant therapy
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Anti-oxidant therapies aiming to reduce the detrimental effects of ROS have so
far yielded conflicting results. Studies of diabetic vessels in vivo have demonstrated
improvements in NO-mediated vasodilation in response to anti-oxidants such as
superoxide dismutase (SOD).54, 55 Additionally, the anti-oxidant properties of vitamin C
have been shown to effectively augment endothelial-dependent vasodilatation in
several studies performed on human forearm vessels, in the setting of diabetes and
hypertension.56-58 Despite promising experimental data, large-scale clinical trials
investigating the effects of anti-oxidant vitamins in patients with diabetes failed to report
any benefits.59, 60 Although conducting clinical trials is a logical progression following
experimental evidence, the discrepancies in these results may indicate that the benefits
of anti-oxidant therapies are too short-term to affect mortality outcomes. The vastly
greater sample size and follow-up period in clinical trials indicates that these results
should take precedent when interpreting the effects of anti-oxidant therapy. However
further experimental evidence regarding the longer-term outcomes of anti-oxidant
therapies is required.
Protein Kinase C
Protein kinase C beta (PKCβ) is an endothelial isoform of the serine/threonine kinase 
family. A host of evidence implicated this enzyme as a chief contributor to endothelial
dysfunction observed in DM.61 PKCβ is activated by diacylglycerol (DAG), which is 
typically produced subsequent to ligand-receptor binding.62 However, in conditions of
high circulating free fatty acids (FFA) and hyperglycaemia, a novel route for the chronic
activation of DAG has been proposed, via de novo synthesis from glucose.63
Significantly increased levels of PKC and DAG have been identified in animal models
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of diabetes.63 Upon activation, PKC induces several intracellular effects, many of which
have been experimentally identified using PKC inhibitors such as ruboxistaurin.43, 64
Such alterations include amplified expression of ET-1, VCAM and ICAM.62 PKC also
activates vascular NADPH oxidase, a significant source of O2•
- and subsequent
oxidative stress in the endothelium. Indeed, inhibition of PKC has been shown to
diminish O2•
- in the diabetic vasculature.65 A trial in healthy humans indicated that PKC
inhibition prevented hyperglycaemia-induced impairment of endothelial-dependent
vasodilation.66 Disappointingly a later trial by the same authors showed that this benefit
was not apparent in T2DM patients,67 suggesting that further work is required to
delineate the role of PKC in T2DM. Additional effects of PKC in the endothelium
include activation of NFkB, alterations in eNOS expression and inhibition of the PI3-K
signalling pathway.43
Hyperglycaemia
The hallmark of DM, chronic hyperglycaemia, has been implicated in the development
of endothelial dysfunction via four principal mechanisms; PKC activation, activation of
the hexosamine and polyol pathways and formation of advanced glycation end-
products (AGEs).68 These pathways are believed to mediate vascular dysfunction
through the unifying mechanism of ROS overproduction, most notably increases in O2•
-.
69 Briefly, the polyol and hexosamine pathways display low affinity for glucose in the
physiological state; however intracellular hyperglycaemia leads to shunting of glucose
through these pathways, with resultant increases in PKC activation, changes in gene
expression and protein function.68 AGEs initially arise from intracellular hyperglycaemia
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and subsequent non-enzymatic reactions, causing alterations in both intra- and extra-
cellular proteins, as well as modifications to the extracellular matrix.70 Additionally,
activation of receptors for AGEs (RAGE) on EC influences ROS production and leads
to NFkB activation which induces atherogenic gene expression.71, 72 Collectively, these
mechanisms have been shown to increase the proton gradient across the inner
mitochondrial membrane, consequently increasing O2•
- as previously discussed. SOD-
enabled inhibition of mitochondrial ROS is capable of inhibiting increases in all these
mechanisms.68
Metabolic memory – role of epigenetics
The mechanisms described suggest routes by which environmental factors such as
diet-induced hyperglycaemia may induce endothelial dysfunction, and it would be easy
to believe that correcting these imbalances would promptly normalise endothelial
function. This is not the case. Indeed, follow-up trials succeeding the DCCT and
UKPDS propose the existence of a so-called ‘metabolic memory’, in which the effects
of either prolonged or transient changes in glycaemia persist long after these have
been re-adjusted.73-75 Not only does this suggest that intensive glycaemic control
cannot completely reverse pre-established hyperglycaemia induced vascular
complications, but importantly showed that the benefits of intensive therapy were
maintained for many years despite a return to often inferior glycaemic control.73 Such
observations have been confirmed in vitro and in vivo, including endothelial cell-specific
studies. 76-78 Together, these data imply that heritable alterations in cell phenotype may
be induced by diabetogenic stimuli, particularly hyperglycaemia. Whilst this was once
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thought to be due to mutations in mitochondrial DNA,68 more recent evidence has
implicated epigenetic mechanisms as the underlying cause of this phenomenon -
alterations in gene expression without changes in DNA sequence.79 Indeed, epigenetic
studies are shedding new light on how environmental factors influence gene
expression and the associated susceptibility to T2DM and increased CV disease.79
Three highly connected pathways provide the foundation for epigenetic theories:
namely post-translational histone modifications, DNA methylation and non-coding
RNA-based mechanisms, detailed studies of which are clearly warranted to investigate
endothelial-specific mechanisms that may inform novel therapeutic targets.
Histone modifications
Post-translational modifications of histones in chromatin alter the conformation of DNA,
providing or denying access to specific sites that enhance or retard gene transcription,
respectively. Histone modifications (e.g. acetylation/deacetylation;
methylation/demethylation) are regulated by a family of enzymes that are responsible
for their transfer (histone acetyltransferases (HATs), histone methyltransferases
(HMTases)); or removal (histone deacetylases (HDAC), histone demethylases
(HDM)).79 Several studies have been performed specifically in endothelial cells, where
changes in the expression and activity of these enzymes have been linked to diabetic
complications. For example, specific histone methylations are associated with the
chronic inflammatory phenotype in EC exposed to high glucose concentrations.80
Transient exposure of human and bovine endothelium to hyperglycaemia led to
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transcriptional activation of inflammatory NFkB-dependent promoters that were
sustained even following restoration of normoglycaemia.80, 81
DNA methylation
Studies examining the role of DNA methylation in diabetes and vascular complications
are few, although altered patterns of DNA methylation have been associated with
atherosclerosis 82 and in the endothelium itself.83 Both global and gene-specific
methylation is believed to contribute to the metabolic memory of diabetic complications.
Covalent methylation of cytosine residues is a stable DNA modification that persists
throughout experimental processing,84 providing a robust platform on which to base
future investigations. Akin to modifications in histones, DNA methylation can confer
persistent alterations in gene expression and a clear understanding of the complex
mechanisms involved will be of immense value. High fat feeding of obese rats has
been reported to induce hypermethylation of particular genes,85 so it is reasonable to
consider that this phenomenon may also exist in human diabetic individuals, and
specifically at the level of the endothelium.
microRNAs
Another area of intense interest in which gene expression can be post-transcriptionally
modified is by microRNAs (miRs), the most widely studied of the non-coding RNAs.
miRs are short RNAs that inhibit expression of a range of target proteins through
mRNA degradation or translational repression. As regards ECs, in vitro studies have
exposed a complex network of miRs with regulatory roles in proliferation and migration
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(miR-320,86 miR-503,87 miR221/222 88-90), inflammation (miR-10a,91 miR-126 92) and
angiogenesis (miR221/222,93 miR-126,94 miR-210,95 miR-21 96). These roles may be
divergent in physiological circumstances, for example specific miRs are capable of
exerting protective, pro-angiogenic effects,94, 95 while others confer more unfavourable
anti-angiogenic properties.93, 96 Furthermore, a distinct signature of miR dysregulation
has been proposed to exist in DM,97 whereby high glucose conditions may induce over
or under expression of detrimental or beneficial miRs respectively, thereby contributing
to the development of vascular complications. In such a way, upregulation of miR-320
was observed in EC exposed to hyperglycaemia, with a resultant reduction in cellular
proliferation and migration.86 Importantly, inhibition of the overexpressed miRs restored
EC regenerative functions.86
The stable and consistent levels of plasma miRs in healthy individuals has identified
them as potential biomarkers for diseases such as T2DM,98 not only for evaluating
disease progression, but also to detect risk of future disease development. In this way,
plasma profiling of T2DM patients has revealed altered levels of miRs which may
contribute to a pathophysiological state.99 Highly reported miRs that appear to
modulate EC function either beneficially or detrimentally are presented in Table 2.
In summary, whilst the study of epigenetic mechanisms associated with
diabetes and its complications has gained momentum in recent years, there is still
much to be learned. Moreover, the complexity of these interactions will pose
considerable challenges for their elucidation.
Current therapies for DM
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Most current treatment options for reducing T2DM-related cardiovascular risk focus on
controlling metabolic imbalances such as hyperglycaemia, hypertension and raised
levels of free fatty acids. Whilst insulin is the obvious treatment of choice in T1DM, first
line action for T2DM is through lifestyle changes. The large-scale Look AHEAD (Action
for Health in Diabetes) trial 100 reported however, that whilst weight loss in DM patients
conferred multiple health benefits, cardiovascular risk remained unchanged.101 Oral
hypoglycaemic drugs aim to correct the pathophysiological features that lead to T2DM
generally by targeting the key characteristic of insulin resistance. Essentially, these
drugs act by either increasing insulin production (insulin secretagogues such as
sulfonylureas, glinides and more recently incretin mimetics) or increasing target tissue
sensitivity (insulin sensitisers such as metformin and thiazolidinediones).102 Whilst there
is genuine optimism that new oral therapies may also contribute to reducing
cardiovascular risk, a systematic review showed metformin to be the only current agent
with such potential.103 Whilst able to reduce levels of glycosylated haemoglobin and
microvascular disease to some degree, oral antidiabetic drugs still fall short of
ameliorating cardiovascular complications in the short or medium term, and importantly
have been implicated in increased mortality from hypoglycaemia 104 or myocardial
infarction.105 Nevertheless, trials have highlighted the importance of early glycaemic
intervention to reduce vascular complications, likely due to the effects of metabolic
memory.
Approach to future therapies
This review has highlighted the critical involvement of endothelial dysfunction in the
pathogenesis of vascular disease in DM, in which diabetic mediators inflict a pro-
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atherogenic, inflammatory phenotype, often with limited or delayed reversibility. Owing
to the silent nature of insulin resistance and hence an inevitable problem in rapid
diagnosis, early intervention is difficult. Manipulation or inhibition of some of the
described mechanisms may provide novel avenues for therapeutic intervention.
However, the transition from this experimental stage through to production of safe and
effective drugs is not easy, and requires results from valid and reliable large-scale
clinical trials. Such clinical trials have already revealed disappointing outcomes
regarding the use of anti-oxidants in alleviating oxidative stress;59, 60 however they
should not deter further anti-oxidant therapy trials. It is likely that a ‘prevention rather
than cure’ approach is preferable in the management of ROS, with the enzymatic
sources of superoxide anion a promising target for future therapeutics.16 Other
mechanisms meriting further investigation include PKC inhibition 65 and the previously
mentioned use of salicylate anti-inflammatory drugs.45
Rapidly accumulating evidence supports the notion that miRs are cell-type
specific and differentially expressed, and may actually play a causative role in diabetes
and its related vascular complications.97 Recent evidence suggests that miRs can be
communicated between cells and specifically, EC-derived plasma miRs are reportedly
able to regulate the biological functions of not only other EC but also vascular smooth
muscle cells and leukocytes (reviewed in 106). In future, understanding and exploiting
these mechanisms has potential to be translated into defining clinical biomarkers and
elucidating specific molecular targets for therapeutics. Longer term, these may be of
value in reversing the devastating outcomes attributed to endothelial dysfunction in
diabetes by erasing persistent metabolic memory by “re-setting” the epigenetic cell
signature.
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Conclusions
Recent advances in knowledge surrounding metabolic memory and the role of
epigenetics have provided exciting new avenues for future research. However, there is
still much to learn regarding their roles in diabetic vascular complications, and
specifically on the EC. To date, in vitro studies of metabolic memory in cultured EC
have largely focused on changes in gene expression in response to hyperglycaemia.80
However, this review has highlighted the contribution of a complex array of factors
other than glucose in the pathogenesis of endothelial dysfunction. For this reason it is
apparent that identifying the presence of a diabetic metabolic memory might be most
accurately observed in EC derived from human diabetic vessels. In such a way, we
have previously identified inherent functional differences between vascular SMC
cultured from patients with and without T2DM;107 such data offering an explanation for
increased venous bypass graft stenosis after revascularisation surgery in these
patients. Identification of any sustained functional differences in T2DM-EC may provide
further justification for the aforementioned graft failure. Such information would
potentially create a foundation upon which therapeutics to ameliorate endothelial
dysfunction could be developed.
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Figure legends
Figure 1. Intracellular insulin signalling pathways. Upon binding to its receptor,
insulin initiates two key intracellular signalling pathways. Activation of PI3-Kinase
dominates under physiological conditions resulting in a net anti-atherogenic effect. In
insulin resistance, selective deficiency in the PI3-Kinase pathway leads to a dominant
MAP kinase pathway, whose effects are predominantly pro-atherogenic.
IRS-1, Insulin substrate receptor-1; PI3-K, Phosphatidylinositol 3- kinase; Akt, Protein
Kinase B; MEK 1/2, Mitogen activated protein kinase/extracellular receptor kinase; Erk
1/2, Extracellular receptor kinase; eNOS, endothelial nitric oxide synthase.
Figure 2. Production of peroxynitrite in endothelial cells. In healthy cells, eNOS
catalyses synthesis of NO from L-arginine. The factors listed (bullet-pointed box)
produce O2• - which reacts with NO to produce ONOO-. This uncouples eNOS from BH4
which enhances O2• - production, and increased ONOO-.
Grey arrows - Physiological processes; Red arrows – Pathological processes; NO –
Nitric oxide; ONOO- - Peroxynitrite; eNOS – endothelial nitric oxide synthase; O2• - -
superoxide anion; BH4 – tetrahydrobiopterin.
Figure 3. Activation and effects of protein kinase C (PKC). High levels of free fatty
acids and hyperglycaemia activate DAG, which in turn activates PKC. This increases
expression of ET-1, VCAM, ICAM, NFkB and NADPH oxidase. NADPH oxidase
activation results in decreased NO bioavailability. PKC may have a role in PI3-kinase
pathway inhibition. Ruboxistaurin inhibits PKC activation.
DAG – diacylglycerol; VCAM – vascular cell adhesion molecule; ICAM – intercellular
adhesion molecule; NFkB – nuclear factor kB; ET1 – endothelin 1; NADPH –
nicotinamide adenine dinucleotide phosphate; PI3-kinase – Phosphoinositide-3 kinase.
Table 1. Inflammatory components of diabetes complications
Key categories of inflammatory mediators associated with vascular complications of
diabetes, indicating the principal components of each category. There is widespread
evidence for inflammatory cytokines, adhesion molecules, chemokines and
transcription factors. More recent data supports roles for profibrotic cytokines and toll-
like receptors that appear to mediate responses to a number of “diabetogenic” stimuli
including hyperglycaemia, ROS and RAGE ligands (reviewed in 40).
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Table 2. Principal endothelial microRNAs and their involvement in cell function.
Effect of miRs on aspects of EC function, together with known specific molecular
targets of each miR. Where reported, changes in miR expression in EC subjected to
high-glucose conditions or altered plasma levels in patients with T2DM are
documented.
VEGF – Vascular endothelial growth factor; FGF – Fibroblast growth factor; IGF –
Insulin-like growth factor; VCAM – Vascular cell adhesion molecule; SDF – Stromal
cell-derived factor; PAK1 – P21-activated kinase 1; SPRED1 – Sprouty-related protein
1; PI3K2 – Phosphoinositol-3 kinase regulatory subunit 2; ERK – Extracellular signal-
regulated kinase; PTEN – Phosphatase and tensin homolog; PPAR – Peroxisome
proliferators activated receptor; PDCD4 – Programmed cell death 4; HOXA –
Homeobox A1; MAP3K7 – Mitogen-activated protein kinase kinase kinase 7; bTRC –
β-transducin repeat-containing gene. 
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Table 1. Categories of the inflammatory
factors linked to the vascular complications
of diabetes
Inflammatory cytokines
 Interleukins IL-1, IL-6, IL-18
 Tumour necrosis factor alpha (TNF-α) 
 C-reactive protein (CRP)
Adhesion molecules
 Intercellular adhesion molecule 1 (ICAM-
1)
 Vascular cell adhesion molecule-1
(VCAM-1)
 E-selectin
Chemokines
 CCL-2 (MCP-1)
 CX3CL1 (fractalkine)
 CCL5 (RANTES)
Transcription factors
 NFkB
Toll-like receptors
 TLR2
 TLR4
Profibrotic cytokines
 Transforming growth factor beta (TGF-β) 
 Connective tissue growth factor (CTGF)
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Micro-RNA Reference Functional endothelial cell
effects
Specific targets Effect of high-glucose
conditions and/or T2DM
miR-320 Wang et al. (86) љWƌŽůŝĨĞƌĂƟŽŶ͕ љD ŝŐƌĂƟŽŶ͕
↓ Angiogenesis
VEGF, FGF, IGF-1 Up-regulated
*Reduced levels observed in plasma of
T2DM patients (99)
miR-503 Caporali et al. (87) љWƌŽůŝĨĞƌĂƟŽŶ,љD ŝŐƌĂƟŽŶ,
↓ Angiogenesis, ↓ Cell cycle 
progression
CDC, CCNE1 Up-regulated
miR-221/222 Togliatto et al. (88);
Liu et al. (89); Li et
al. (90); Dentelli et
al. (93)
љWƌŽůŝĨĞƌĂƟŽŶ, љD ŝŐƌĂƟŽŶ͕ 
↓angiogenesis, ↑ Apoptosis
Ckit, p27kip1,
p57kip2
Up-regulated/Down-regulated
*Conflicting results
miR-126 Wang et al. (94) ;
Fish et al. (92)
љ/ŶŇĂŵŵĂƟŽŶ͕ ј angiogenesis VCAM1, SDF-1,
PAK1, SPRED1,
PI3KR2
Not reported
*Reduced levels observed in plasma of
T2DM patients (99)
miR-210 Fasanaro et al. (95) ↑ Angiogenesis Ephrin A3 Not reported
miR-21 Sabatel et el. (96) ј /ŶŇĂŵŵĂƟŽŶ͕ ↓angiogenesis ERK, PTEN, RhoB, 
PPARα, Bcl2, PDCD4
Not reported
*Reduced levels observed in plasma of
T2DM patients (99)
miR-10a Fang et al. (91) љ/ŶŇĂŵŵĂƟŽŶ HOXA, MAP3K7,
bTRC
Not reported
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